Sangamo Therapeutics, Inc. (PNK: SGMO) Stock Competitors & Peer Comparison

Sangamo Therapeutics, Inc. (PNK: SGMO) plays a significant role within the Healthcare sector. Its performance on the PNK reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SGMO stands at 30.7M. In comparison, ADTX has a market cap of 3.7M. Regarding current trading prices, SGMO is priced at $0.07 on the PNK, while ADTX trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SGMO currently has a P/E ratio of -0.20, whereas ADTX's P/E ratio is N/A. In terms of profitability, SGMO's ROE is +66.86%, compared to ADTX's ROE of +9.26%. Regarding short-term risk, SGMO is more volatile compared to ADTX. This indicates higher risk in terms of short-term price fluctuations for SGMO.Check ADTX's competition here

Sangamo Therapeutics, Inc. (PNK: SGMO) plays a significant role within the Healthcare sector. Its performance on the PNK reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SGMO stands at 30.7M. In comparison, ITRMF has a market cap of 2.7M. Regarding current trading prices, SGMO is priced at $0.07 on the PNK, while ITRMF trades at $0.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SGMO currently has a P/E ratio of -0.20, whereas ITRMF's P/E ratio is -0.07. In terms of profitability, SGMO's ROE is +66.86%, compared to ITRMF's ROE of +4.42%. Regarding short-term risk, SGMO is more volatile compared to ITRMF. This indicates higher risk in terms of short-term price fluctuations for SGMO.Check ITRMF's competition here

Sangamo Therapeutics, Inc. (PNK: SGMO) plays a significant role within the Healthcare sector. Its performance on the PNK reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SGMO stands at 30.7M. In comparison, CASIF has a market cap of 2.6M. Regarding current trading prices, SGMO is priced at $0.07 on the PNK, while CASIF trades at $0.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SGMO currently has a P/E ratio of -0.20, whereas CASIF's P/E ratio is -0.05. In terms of profitability, SGMO's ROE is +66.86%, compared to CASIF's ROE of +2.04%. Regarding short-term risk, SGMO is more volatile compared to CASIF. This indicates higher risk in terms of short-term price fluctuations for SGMO.Check CASIF's competition here

Sangamo Therapeutics, Inc. (PNK: SGMO) plays a significant role within the Healthcare sector. Its performance on the PNK reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SGMO stands at 30.7M. In comparison, OCEA has a market cap of 237.3K. Regarding current trading prices, SGMO is priced at $0.07 on the PNK, while OCEA trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SGMO currently has a P/E ratio of -0.20, whereas OCEA's P/E ratio is N/A. In terms of profitability, SGMO's ROE is +66.86%, compared to OCEA's ROE of +0.04%. Regarding short-term risk, SGMO is less volatile compared to OCEA. This indicates lower risk in terms of short-term price fluctuations for SGMO.Check OCEA's competition here

Sangamo Therapeutics, Inc. (PNK: SGMO) plays a significant role within the Healthcare sector. Its performance on the PNK reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SGMO stands at 30.7M. In comparison, AFMDQ has a market cap of 1.6K. Regarding current trading prices, SGMO is priced at $0.07 on the PNK, while AFMDQ trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SGMO currently has a P/E ratio of -0.20, whereas AFMDQ's P/E ratio is N/A. In terms of profitability, SGMO's ROE is +66.86%, compared to AFMDQ's ROE of -1.01%. Regarding short-term risk, SGMO is more volatile compared to AFMDQ. This indicates higher risk in terms of short-term price fluctuations for SGMO.Check AFMDQ's competition here

Sangamo Therapeutics, Inc. (PNK: SGMO) plays a significant role within the Healthcare sector. Its performance on the PNK reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SGMO stands at 30.7M. In comparison, BIORQ has a market cap of 905. Regarding current trading prices, SGMO is priced at $0.07 on the PNK, while BIORQ trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SGMO currently has a P/E ratio of -0.20, whereas BIORQ's P/E ratio is N/A. In terms of profitability, SGMO's ROE is +66.86%, compared to BIORQ's ROE of +1.22%. Regarding short-term risk, SGMO is more volatile compared to BIORQ. This indicates higher risk in terms of short-term price fluctuations for SGMO.Check BIORQ's competition here